Anticancer activity using positron emission tomography-computed tomography and pharmacokinetics of β-eudesmol in human cholangiocarcinoma xenografted nude mouse model

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 3, 2015, Pages 293-304

  Plengsuriyakarn, Tullayakorn ^a   Karbwang, Juntra ^b   Na Bangchang, Kesara ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Anti CCA; Cholangiocarcinoma; Pharmacokinetics; Positron emission tomography computed tomography; eudesmol

Indexed keywords

BETA EUDESMOL; FLUORODEOXYGLUCOSE F 18; TECHNETIUM 99M; ANTINEOPLASTIC AGENT; BETA-EUDESMOL; SESQUITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BODY WEIGHT; CANCER DIAGNOSIS; CANCER INHIBITION; CELL VIABILITY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; ELIMINATION HALF-LIFE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; INVESTIGATIVE PROCEDURES; LOW DRUG DOSE; LUNG METASTASIS; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; NUDE MOUSE; SINGLE DRUG DOSE; SURVIVAL TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VOLUME OF DISTRIBUTION; ABSORPTION; ANIMAL; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG SCREENING; FEMALE; INTRAHEPATIC BILE DUCT; MALE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ABSORPTION, PHYSICOCHEMICAL; ANIMALS; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; SESQUITERPENES, EUDESMANE; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922678898     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12354     Document Type: Article

References (25)

1. Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit. Rev. Oncol. Hematol. 2009; 69: 259-70.
2. Singh MK, Facciuto ME. Current management of cholangiocarcinoma. Mt. Sinai J. Med. 2012; 79: 232-45.
3. Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop. Med. Int. Health 2004; 9: 588-94.
4. Sithithaworn P, Andrews RH, Nguyen VD et al. The current status of opisthorchiasis and clonorchiasis in the Mekong Basin. Parasitol. Int. 2012; 61: 10-16.
5. Tsuneki H, Ma EL, Kobayashi S, Sekizaki N, Maekawa K, Sasaoka T. Antiangiogenic activity of beta-eudesmol in vitro and in vivo. Eur. J. Pharmacol. 2005; 512: 105-15.
6. Mahavorasirikul W, Viyanant V, Chaijaroenkul W, Itharat A, Na-Bangchang K. Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. BMC Complement. Altern. Med. 2010; 10: 55.
7. Plengsuriyakarn T, Viyanant V, Eursitthichai V, Na-Bangchang K. In vitro investigations on the potential roles of Thai medicinal plants in treatment of cholangiocarcinoma. Int. Res. Pharm. Pharmacol. 2012; 2: 52-63.
8. Plengsuriyakarn T, Viyanant V, Eursitthichai V et al. Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. BMC Complement. Altern. Med. 2012; 12: 23.
9. Xiao PG, Li DP, Yang SL. Modern Chinese Materia Medica. Chemical Industry Press, Beijing. 2002.
10. Ma EL, Li YC, Tsuneki H et al. Beta-eudesmol suppresses tumour growth through inhibition of tumour neovascularisation and tumour cell proliferation. J. Asian Nat. Prod. Res. 2008; 10: 159-67.
11. Chiou LC, Chang CC. Antagonism by beta-eudesmol of neostigmine-induced neuromuscular failure in mouse diaphragms. Eur. J. Pharmacol. 1992; 216: 199-206.
12. Nojima H, Kimura I, Kimura M. Blocking action of succinylcholine with beta-eudesmol on acetylcholine-activated channel activity at endplates of single muscle cells of adult mice. Brain Res. 1992; 575: 337-40.
13. Kimura M, Nojima H, Muroi M, Kimura I. Mechanism of the blocking action of beta-eudesmol on the nicotinic acetylcholine receptor channel in mouse skeletal muscles. Neuropharmacology 1991; 30: 835-41.
14. Kelloff GJ, Hoffman JM, Johnson B et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res. 2005; 11: 2785-808.
15. Cherry SR, Gambhir SS. Use of positron emission tomography in animal research. ILAR J. 2001; 42: 219-32.
16. Breitenstein S, Apestegui C, Clavien PA. Positron emission tomography (PET) for cholangiocarcinoma. HPB (Oxford) 2008; 10: 120-1.
17. Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJr. Am. J. Roentgenol. 2011; 197: 260-5.
18. Laverman P, Blokx WA, Te Morsche RH et al. [(18)F]FDG accumulation in an experimental model of multistage progression of cholangiocarcinoma. Hepatol. Res. 2007; 37: 127-32.
19. Yeh CN, Lin KJ, Hsiao IT et al. Animal PET for thioacetamide-induced rat cholangiocarcinoma: A novel and reliable platform. Mol. Imaging Biol. 2008; 10: 209-16.
20. Chang CH, Jan ML, Fan KH et al. Longitudinal evaluation of tumor metastasis by an FDG-microPet/microCT dual-imaging modality in a lung carcinoma-bearing mouse model. Anticancer Res. 2006; 26: 159-66.
21. Deroose CM, De A, Loening AM et al. Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging. J. Nucl. Med. 2007; 48: 295-303.
22. 99mTc receptor imaging agents. Trans. Met. Chem. 1997; 22: 318-20.
23. Wongkajornsilp A, Wamanuttajinda V, Kasetsinsombat K et al. Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3 CD56 subset through the co-culturing dendritic cells. PLoS One 2013; 8: e78980.
24. Singh AK, Verma J, Bhatnagar A, Sen S, Bose M. Tc-99m isoniazid: A specific agent for diagnosis of tuberculosis. World J. Nucl. Med. 2003; 2: 292-305.
25. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Programs Biomed. 2010; 99: 306-14.